DDInter915 DDInter119
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Indacaterol {u} (Compound) resembles {v} (Compound) Procaterol
Indacaterol {u} (Compound) treats {v} (Disease) asthma
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Indacaterol (Compound) resembles Procaterol (Compound)
Indacaterol (Compound) treats asthma (Disease)
Indacaterol (Compound) binds ADRB1 (Gene)
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Indacaterol (Compound) causes Cardiac disorder (Side Effect)